Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Delcath Systems (DCTH) PT Raised to $20 at BTIG
August 6, 2024 4:57 AM EDTBTIG analyst Marie Thibault raised the price target on Delcath Systems (NASDAQ: DCTH) to $20.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "The U.S. commercial launch is ramping quicker than we initially expected with Delcath Systems reporting total Q2 sales of $7.8M, including $6.6M from Hepzato and $1.2M from OUS Chemosat sales. This was well above consensus of $5.2M. Seven treating centers were active in the quarter, performing what we estimate were 36 combined... More
